Evaluation of N-terminal pro-B type natriuretic peptide analysis on the Elecsys™ 1010 and 2010 analysers

被引:41
作者
Barnes, S
Collinson, PO
Galasko, G
Lahiri, A
Senior, R
机构
[1] Univ London St Georges Hosp, Dept Chem Pathol, London, England
[2] Northwick Pk Hosp & Clin Res Ctr, Dept Cardiovasc Med, Harrow HA1 3UJ, Middx, England
关键词
D O I
10.1258/0004563042466848
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background N-terminal pro-B type natriuretic peptide (NTpBNP) is a potential marker of cardiac failure. Methods The Roche ElecsysR(TM) 1010 and 2010 assays for NTpBNP were 2 evaluated for precision, sample stability, and correlation between sample types and with other natriuretic peptides. Samples from 290 individuals aged 45-89 years with no cardiovascular risk factors, renal failure, electrocardiogram changes, evidence of structural abnormalities, or wall motion abnormalities on echocardiography and with an ejection fraction >50% were used to provide reference NTpBNP ranges. Results The intra-assay imprecision was < 10% across the analytical range and < 3% at all concentrations analysed > 30 ng/L. Inter-assay imprecision was 5.36.7% on the Elecsys 1010 and 4.4-5.0% on the Elecsys 2010, in the range 380-13000ng/L. There was no statistically significant change in NTpBNP following storage in whole-blood samples at room temperature for 24 h before centrifugation; serum samples at room temperature for 7 days, at 4 degreesC for up to 11 days on clotactivation gel or 22 days separated from the gel. NTpBNP concentrations were stable throughout five freeze-thaw cycles. There was a close correlation between NTpBNP concentrations in matched serum, EDTA plasma and lithium-heparin plasma samples. NTpBNP and BNP were more closely associated than were N-terminal proatrial natriuretic peptide and NTpBNP. This association was stronger at lower concentrations. NTpBNP concentrations increased with age, with values higher in women than men. Conclusions NTpBNP is a stable molecule that can be measured easily and precisely using the Roche Elecsys 1010 or 2010 immunoassay analysers.
引用
收藏
页码:459 / 463
页数:5
相关论文
共 5 条
[1]   Brain natriuretic peptide as bridge to therapy for heart failure [J].
Dries, DL ;
Stevenson, LW .
LANCET, 2000, 355 (9210) :1112-1113
[2]  
HOBBS FDR, 2002, BMJ-BRIT MED J, V324, P1
[3]   Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment [J].
Hunt, PJ ;
Richards, AM ;
Nicholls, MG ;
Yandle, TG ;
Doughty, RN ;
Espiner, EA .
CLINICAL ENDOCRINOLOGY, 1997, 47 (03) :287-296
[4]   ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the evaluation and management of heart failure) [J].
Hunt, SA ;
Baker, DW ;
Chin, MH ;
Cinquegrani, MP ;
Feldman, AM ;
Francis, GS ;
Ganiats, TG ;
Goldstein, S ;
Gregoratos, G ;
Jessup, ML ;
Noble, RJ ;
Packer, M ;
Silver, MA ;
Stevenson, LW ;
Gibbons, RJ ;
Antman, EM ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Jacobs, AK ;
Hiratzka, LF ;
Russell, RO ;
Smith, SC .
CIRCULATION, 2001, 104 (24) :2996-3007
[5]   Guidelines for the diagnosis and treatment of chronic heart failure [J].
Remme, WJ ;
Swedberg, K .
EUROPEAN HEART JOURNAL, 2001, 22 (17) :1527-1560